A Comparison of Two Types of Injected Nutritional Supplements in Patients With AIDS and Pneumocystis Carinii Pneumonia (PCP)
|ClinicalTrials.gov Identifier: NCT00002275|
Recruitment Status : Completed
First Posted : August 31, 2001
Last Update Posted : February 20, 2009
The objectives of this study are:
To establish whether there is a difference in clinical effectiveness of Liposyn II 20 percent as compared with Liposyn III 2 percent in AIDS patients with Pneumocystis carinii pneumonia (PCP). To compare the effects of the two lipid emulsions on immunologic function in AIDS patients. To compare the effect of the two lipid emulsions on HIV load in AIDS patients as measured by reverse transcriptase (RT) in culture. To determine whether a decrease in HIV infectivity is greater in patients given a parenteral feeding regimen containing Liposyn II 20 percent or Liposyn III 2 percent.
|Condition or disease||Intervention/treatment|
|HIV Infections||Drug: Fat Emulsion 2% Drug: Fat Emulsion 20%|
|Study Type :||Interventional (Clinical Trial)|
|Official Title:||Lipid-Based Parenteral Nutritional Support in Patients With the Acquired Immunodeficiency Syndrome and Pneumocystis Carinii Pneumonia. A Comparison of Two Lipid Formulations|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00002275
|United States, New Jersey|
|East Orange Veterans Administration Med Ctr|
|East Orange, New Jersey, United States, 07018|